These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34715784)

  • 1. Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device- a pilot study.
    Winter A; Zacharowski K; Meybohm P; Schnitzbauer A; Ruf P; Kellermann C; Lindhofer H
    BMC Anesthesiol; 2021 Oct; 21(1):261. PubMed ID: 34715784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
    Seimetz D; Lindhofer H; Bokemeyer C
    Cancer Treat Rev; 2010 Oct; 36(6):458-67. PubMed ID: 20347527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
    English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro.
    Seeber A; Martowicz A; Spizzo G; Buratti T; Obrist P; Fong D; Gastl G; Untergasser G
    BMC Cancer; 2015 May; 15():372. PubMed ID: 25947366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines.
    Kubo M; Umebayashi M; Kurata K; Mori H; Kai M; Onishi H; Katano M; Nakamura M; Morisaki T
    Anticancer Res; 2018 Jul; 38(7):4273-4279. PubMed ID: 29970561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catumaxomab: clinical development and future directions.
    Linke R; Klein A; Seimetz D
    MAbs; 2010; 2(2):129-36. PubMed ID: 20190561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo.
    Dettmar K; Seitz-Merwald I; Lindemann C; Schroeder P; Seimetz D; Atz J
    Clin Transl Oncol; 2012 May; 14(5):376-81. PubMed ID: 22551544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety of cell salvage in tumor surgery : Systematic review with meta-analysis].
    Frietsch T; Steinbicker AU; Hackbusch M; Nguyen XD; Dietrich G
    Anaesthesist; 2020 May; 69(5):331-351. PubMed ID: 32221621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catumaxomab: a bispecific trifunctional antibody.
    Sebastian M; Kuemmel A; Schmidt M; Schmittel A
    Drugs Today (Barc); 2009 Aug; 45(8):589-97. PubMed ID: 19927225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting.
    Atanackovic D; Reinhard H; Meyer S; Spöck S; Grob T; Luetkens T; Yousef S; Cao Y; Hildebrandt Y; Templin J; Bartels K; Lajmi N; Stoiber H; Kröger N; Atz J; Seimetz D; Izbicki JR; Bokemeyer C
    Hum Vaccin Immunother; 2013 Dec; 9(12):2533-42. PubMed ID: 23955093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer.
    Ruf P; Gires O; Jäger M; Fellinger K; Atz J; Lindhofer H
    Br J Cancer; 2007 Aug; 97(3):315-21. PubMed ID: 17622246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient blood management in elective total hip- and knee-replacement surgery (Part 1): a randomized controlled trial on erythropoietin and blood salvage as transfusion alternatives using a restrictive transfusion policy in erythropoietin-eligible patients.
    So-Osman C; Nelissen RG; Koopman-van Gemert AW; Kluyver E; Pöll RG; Onstenk R; Van Hilten JA; Jansen-Werkhoven TM; van den Hout WB; Brand R; Brand A
    Anesthesiology; 2014 Apr; 120(4):839-51. PubMed ID: 24424070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro.
    Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M; Morisaki T
    Anticancer Res; 2014 Aug; 34(8):4509-19. PubMed ID: 25075094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).
    Jäger M; Schoberth A; Ruf P; Hess J; Hennig M; Schmalfeldt B; Wimberger P; Ströhlein M; Theissen B; Heiss MM; Lindhofer H
    Cancer Res; 2012 Jan; 72(1):24-32. PubMed ID: 22044753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient blood management in elective total hip- and knee-replacement surgery (part 2): a randomized controlled trial on blood salvage as transfusion alternative using a restrictive transfusion policy in patients with a preoperative hemoglobin above 13 g/dl.
    So-Osman C; Nelissen RG; Koopman-van Gemert AW; Kluyver E; Pöll RG; Onstenk R; Van Hilten JA; Jansen-Werkhoven TM; van den Hout WB; Brand R; Brand A
    Anesthesiology; 2014 Apr; 120(4):852-60. PubMed ID: 24434302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometric evaluation of the safety of intraoperative salvaged blood filtered with leucocyte depletion filter in spine tumour surgery.
    Kumar N; Lam R; Zaw AS; Malhotra R; Tan J; Tan G; Setiobudi T
    Ann Surg Oncol; 2014 Dec; 21(13):4330-5. PubMed ID: 25069862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab.
    Seeber A; Braicu I; Untergasser G; Nassir M; Fong D; Botta L; Gastl G; Fiegl H; Zeimet A; Sehouli J; Spizzo G
    Oncotarget; 2015 Sep; 6(28):25017-23. PubMed ID: 26296970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are we ready for the use of intraoperative salvaged blood in metastatic spine tumour surgery?
    Kumar N; Ahmed Q; Lee VK; Zaw AS; Goy R; Wong HK
    Eur Spine J; 2016 Dec; 25(12):3997-4007. PubMed ID: 26188770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
    Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.